These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 14521488)

  • 41. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
    Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
    Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drotrecogin alfa (activated) in South African private hospital ICUs.
    Hodgson RE; Williams PG; Foden AP; Grolman D
    S Afr Med J; 2003 Jul; 93(7):474-5. PubMed ID: 12939910
    [No Abstract]   [Full Text] [Related]  

  • 43. Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden.
    Hjelmgren J; Persson U; Tennvall GR
    Am J Ther; 2005; 12(5):425-30. PubMed ID: 16148428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacist intervention in activated protein C therapy for severe sepsis: influence on health and economic outcomes.
    Chan AL; Hsieh HJ; Lin SJ
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):229-35. PubMed ID: 19356388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe sepsis: patient management focusing on administration of drotrecogin alpha (activated) infusion.
    Riddell C; Blackwood B
    Nurs Crit Care; 2006; 11(1):7-15. PubMed ID: 16471293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
    Heslet L; Nielsen JD; Schierbeck J; Andersen JS
    Ugeskr Laeger; 2004 Mar; 166(11):997-1002. PubMed ID: 15049234
    [No Abstract]   [Full Text] [Related]  

  • 47. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Bartelink AK
    Ned Tijdschr Geneeskd; 2006 Feb; 150(7):352-4. PubMed ID: 16523795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activated protein C (Xigris) treatment in sepsis: a drug in trouble.
    Gårdlund B
    Acta Anaesthesiol Scand; 2006 Sep; 50(8):907-10. PubMed ID: 16923083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Substantiating the concerns about recombinant human activated protein C use in sepsis.
    Deans KJ; Minneci PC; Banks SM; Natanson C; Eichacker PQ
    Crit Care Med; 2004 Dec; 32(12):2542-3. PubMed ID: 15599164
    [No Abstract]   [Full Text] [Related]  

  • 50. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification.
    Laterre PF; Wittebole X
    Crit Care; 2003 Dec; 7(6):445-50. PubMed ID: 14624684
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drotrecogin alfa (activated) treatment in severe sepsis: a "journal club" review of the global ENHANCE trial.
    Farmer JC
    Crit Care Med; 2005 Oct; 33(10):2428-31. PubMed ID: 16215411
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Focal surgery, antibiotic therapy--and then? The role of rhAPC in sepsis].
    Spies C; Otter H; Zuckermann-Becker H; Kox WJ
    Kongressbd Dtsch Ges Chir Kongr; 2002; 119():834-43. PubMed ID: 12704933
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
    Yan SB; Nelson DR
    Crit Care Med; 2004 May; 32(5 Suppl):S239-46. PubMed ID: 15118525
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of patients with severe sepsis, treated by drotrecogin alfa (activated).
    Laterre PF; Heiselman D
    Am J Surg; 2002 Dec; 184(6A Suppl):S39-46. PubMed ID: 12521616
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human recombinant activated protein C for severe sepsis.
    Martí-Carvajal AJ; Solà I; Lathyris D; Cardona AF
    Cochrane Database Syst Rev; 2012 Mar; (3):CD004388. PubMed ID: 22419295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Appraisal of treatment for severe sepsis in intensive care units.
    Burchell M; Ruiz F; Barnett D
    Ann R Coll Surg Engl; 2005 Jul; 87(4):283-4. PubMed ID: 16888847
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.